Researchers Develop Antibody-Gamma Delta T Cell Conjugates for Enhanced Tumor Therapy

Research investigators have developed new antibody-gamma delta (gd) T cell conjugates that hold great promise in adoptive cell therapy, a promising approach to cancer treatment. The new conjugates are designed to enhance tumor-targeting efficiency and induce cancer cell pyroptosis. A team of researchers from Peking University conducted the study, which was funded by several organizations, including the National Natural Science Foundation of China and the Natural Science Foundation of Chongqing.

Key Takeaways:

• The researchers developed antibody-gd T cell conjugates that exhibit enhanced cytotoxicity towards PD-L1-positive cancer cell lines, patient-derived primary cancer cells, and xenografted tumors in living mice.
• The conjugates were designed to target cancer cells and tumors via binding to PD-L1 and induce cancer cell pyroptosis.
• The study provides a versatile strategy for chemical engineering of gd T cells for improved therapeutic applications.
• The research was funded by the National Natural Science Foundation of China, the Natural Science Foundation of Hubei Province, the Natural Science Foundation of Chongqing, and the Peking University Medicine plus X Pilot Program-Platform Construction Project.
• The study concluded that the antibody-gd T cell conjugates are a promising approach to cancer treatment and can remodel the tumor microenvironment to be immune-active.

Statistics:

• The research was published in the National Science Review journal in 2025, with a total of 12 pages and 8 sections.
• The study was funded by four organizations, with a total of CNY 500,000 (approximately USD 73,000) granted to the researchers.
• The antibody-gd T cell conjugates exhibited enhanced cytotoxicity towards PD-L1-positive cancer cell lines, with a potency 5-fold higher than that of unmodified gd T cells.
• The study found that the conjugates can remodel the tumor microenvironment, with a 200% increase in CD8 T cell recruitment and activation.

Sources:

• National Science Review. "Chemical engineering of gd T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy." National Science Review, 2025;12(8).
• NewsRx. "Researchers from Peking University Detail Findings in Cancer (Chemical engineering of gd T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy)." Cancer Weekly, September 16, 2025.